List of Vonjo drug patents

Vonjo is owned by Cti Biopharma Corp.

Vonjo contains Pacritinib Citrate.

Vonjo has a total of 3 drug patents out of which 0 drug patents have expired.

Vonjo was authorised for market use on 28 February, 2022.

Vonjo is available in capsule;oral dosage forms.

Vonjo can be used as use of pacritinib for inhibiting janus associated kinase 2(jak2); treatment of myelofibrosis with pacritinib, treatment of myelofibrosis with pacritinib; use of pacritinib for inhibiting janus associated kinase 2(jak2).

Drug patent challenges can be filed against Vonjo from 2026-02-28.

The generics of Vonjo are possible to be released after 25 March, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153632 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
Jan, 2029

(5 years from now)

US8980873 CTI BIOPHARMA CORP 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Mar, 2030

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
May, 2028

(4 years from now)

Do you want to check out VONJO patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 28, 2029
New Chemical Entity Exclusivity (NCE) Feb 28, 2027

Drugs and Companies using PACRITINIB CITRATE ingredient

NCE-1 date: 2026-02-28

Market Authorisation Date: 28 February, 2022

Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib

Dosage: CAPSULE;ORAL

More Information on Dosage

VONJO family patents

17

United States

6

Korea, Republic of

4

Singapore

4

Taiwan

3

Spain

3

Hong Kong

3

Denmark

3

Poland

3

China

3

Canada

3

Japan

3

Portugal

3

Australia

3

European Union

2

Malaysia

2

Brazil

2

Argentina

2

New Zealand

2

Cyprus

2

South Africa

2

Slovenia

1

Austria

1

Germany

1

Russia

1

Croatia

1

Israel

1

Mexico

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic